Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Colorectal Neoplasms 75Carcinoma, Hepatocellular 47Ovarian Neoplasms 40Carcinoma, Non-Small-Cell Lung 26Neoplasms 22Fallopian Tube Neoplasms 17Lung Neoplasms 15Breast Neoplasms 13Neoplasm Metastasis 12Glioblastoma 12Endometrial Neoplasms 12Brain Neoplasms 12Colonic Neoplasms 11Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Uterine Cervical Neoplasms 9Liver Neoplasms 9Stomach Neoplasms 8Colorectal Cancer Metastatic 7Pancreatic Neoplasms 6Advanced Solid Tumors 6Recurrence 5Melanoma 5Glioma 5Carcinoma, Renal Cell 5Carcinoma, Ovarian Epithelial 5Biliary Tract Neoplasms 5Solid Tumor 4Meningeal Carcinomatosis 4Adenocarcinoma of Lung 4

Interventions

Paclitaxel 2tremelimumab 1trastuzumab deruxtecan 1poly ICLC 1pembrolizumab 1osimertinib 1eribulin 1durvalumab 1cemiplimab 1Vascular Endothelial Growth Factor A 1Radiotherapy 1Peptides 1Doxorubicin 1Docetaxel 1Carboplatin 1Capecitabine 1Bevacizumab 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Diabetes Mellitus, Insulin-Dependent, 12 × Bevacizumab × Clear all
NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

GI Innovation, Inc.

Phase 1/2 Recruiting
358 enrolled
DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡